A natural composition for medical purposes, more specifically including procyanidins, for use in the prevention or treatment of endothelial inflammation and/or endothelial systemic dysfunction triggered by Corona virus disease 2019 (COVID-19) including symptomatic post-COVID-19 subjects recovering from COVID-19.

The invention provides antimicrobial compositions comprising charged cellulose nanofibrils dispersed in an aqueous solution having a dissolved oxygen content of at least 20 mg/L, preferably from 20 to 100 mg/L. The cellulose nanofibrils may have an increased surface charge due to their carboxylic acid content which contributes to their antimicrobial properties. In particular, the carboxylic acid content may be at least about 1000 μmol/g cellulose, preferably at least about 1400 μmol/g cellulose. The compositions are suitable for use in the treatment of wounds, in particular chronic wounds.

An astringency reducing agent including an arabinogalactan which has a molecular weight of from 10,000 to 1,000,000 and a ratio of 1,3-bound galactose to total galactose of 12 mol % or more, as an active ingredient. A method for reducing astringency, including blending the astringency reducing agent into an oral product including an astringent substance.

An anti-inflammatory liquid composition for covering oral mucosa includes: a rosin; a shellac; and a solvent. A content of the rosin is 1 wt % or more and 15 wt % or less relative to a total amount of the composition. A content of the shellac is 35 wt % or more and 45 wt % or less relative to the total amount of the composition. A total content of the rosin, the shellac, and a copal is 45 wt % or more and 55 wt % or less relative to the total amount of the composition.

An anti-inflammatory liquid composition for covering oral mucosa includes: a rosin; a shellac; and a solvent. A content of the rosin is 1 wt % or more and 15 wt % or less relative to a total amount of the composition. A content of the shellac is 35 wt % or more and 45 wt % or less relative to the total amount of the composition. A total content of the rosin, the shellac, and a copal is 45 wt % or more and 55 wt % or less relative to the total amount of the composition.

An anti-inflammatory liquid composition for covering oral mucosa includes: a rosin; a shellac; and a solvent. A content of the rosin is 1 wt % or more and 15 wt % or less relative to a total amount of the composition. A content of the shellac is 35 wt % or more and 45 wt % or less relative to the total amount of the composition. A total content of the rosin, the shellac, and a copal is 45 wt % or more and 55 wt % or less relative to the total amount of the composition.

The present disclosure provides methods for treating and preventing foot pain, muscle soreness, inflammation or an inflammatory-related disorder, and itch with the administration of compositions comprising pine resin. Also provided are methods of repelling an insect by applying to a subject composition comprising pine resin.

The present disclosure provides methods for treating and preventing foot pain, muscle soreness, inflammation or an inflammatory-related disorder, and itch with the administration of compositions comprising pine resin. Also provided are methods of repelling an insect by applying to a subject composition comprising pine resin.

The present disclosure provides methods for treating and preventing foot pain, muscle soreness, inflammation or an inflammatory-related disorder, and itch with the administration of compositions comprising pine resin. Also provided are methods of repelling an insect by applying to a subject composition comprising pine resin.

Topical formulations of L-ascorbic acid dissolved in a combination of a urea agent and a non-aqueous skin-compatible solvent are provided. The formulations are storage stable for an extended period of time without significant degradation of the L-ascorbic acid in the composition, are have desirable physical properties. The topical formulations can include high concentrations of the L-ascorbic acid. The topical formulations can include cinnamic acid or derivatives thereof as a penetration enhancer and stabilizing component of ascorbic acid. Topical compositions of this disclosure find use in treating or preventing a variety of cosmetic and/or dermatological conditions as well as to reduce the appearance of chronological and/or environmentally-caused skin aging.